Pharma News
11 Jan 2026 to 17 Jan 2026
Jan 17, 2026
Alto Neuroscience secures US patent for ALTO-207, enhancing its intellectual property portfolio for patient care.
Alto Neuroscience Inc. announced the issuance of US Patent 12,521,374 for ALTO-207, a combination of pramipexole and ondansetron, aimed at treating treatment-resistant depression. The patent protects the method of using ondansetron to reduce pramipexole's side effects, allowing higher doses for better antidepressant effects. The company emphasizes the patent's role in strengthening its intellectual property portfolio and long-term commercial prospects.
Jan 17, 2026
US Supreme Court to review patent dispute over 'skinny label' with Amarin
The U.S. Supreme Court will hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa, following an appeal from Hikma Pharmaceuticals. The case could impact generic drug makers and "skinny labels" that omit patented uses. Amarin accuses Hikma of promoting its generic version in ways that infringe on Amarin's patents. The outcome may affect generic competition significantly.
Jan 17, 2026
SCHOTT Pharma: The Unseen Foundation Supporting the Growth of Injectable Medications
SCHOTT Pharma is emerging as a key player in the injectable biotech and pharma sector, providing advanced glass and polymer systems for drug containment. Their products, including FIOLAX® vials and prefilled syringes, enhance drug stability and safety. As demand for complex injectables rises, SCHOTT Pharma's focus on high-performance solutions positions it favorably against competitors like Gerresheimer and Stevanato.
Jan 16, 2026
The Tinderbox Sparks Controversy: Supreme Court to Rule on Generic Equivalence Claims...
The Supreme Court has agreed to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., focusing on whether generic drug manufacturers can be liable for induced infringement when using "skinny labels." The case involves Hikma's generic version of Amarin's Vascepa (icosapent ethyl), approved only for severe hypertriglyceridemia, while omitting the patented cardiovascular use. The outcome may impact pharmaceutical competition and patent liability.
Jan 16, 2026
Takeda's R&D Executive Discusses Potential of $1.2 Billion Agreement as a Major Value Opportunity in...
Takeda Pharmaceutical has acquired rights to two drugs from Innovent Biologics for $1.2 billion, enhancing its oncology pipeline. The main asset, TAK-928, is a bispecific antibody targeting PD-1 and IL-2, while TAK-921 is an antibody-drug conjugate for gastrointestinal cancers. Takeda aims to leverage these assets to address unmet needs in cancer treatment, with potential milestone payments reaching $10.2 billion.
Jan 16, 2026
Judge's Reversal on Stelara Renders Trial 'Unnecessary' - Law360 Healthcare Authority
A Virginia judge's reversal has led to the conclusion that a trial regarding CareFirst's lawsuit against Johnson & Johnson over alleged anticompetitive practices related to the immunosuppressive drug Stelara is "no longer warranted." The suit accused J&J of using merger and patent fraud to protect Stelara from competition.
Jan 16, 2026
Federal Circuit Invalidates Life Sciences Patent Due to Inadequate Disclosure of Specific Species
The Federal Circuit ruled in Seagen v. Daiichi Sankyo that general disclosures in patent applications are insufficient to support specific claims. The court invalidated Seagen's patent for the ADC Enhertu®, stating that the specific GGFG linker was not adequately described in the priority application. This decision emphasizes the need for detailed disclosures in life sciences patents.
Jan 16, 2026
Alteogen is broadening its discussions for technology transfer with international pharmaceutical companies...
Alteogen is advancing its subcutaneous injection platform 'ALT-B4' and is in negotiations with about 10 global pharmaceutical companies for technology transfer, following successful commercialization of Merck's Keytruda SC formulation. CEO Jeon Tae-yeon announced plans for additional contracts and highlighted ongoing development in obesity treatments and long-term insulin drugs at the JPMorgan Healthcare Conference APAC.
Jan 16, 2026
Federal Circuit Invalidates Life Sciences Patent Due to Inadequate Disclosure of Specific Species
The Federal Circuit ruled in Seagen v. Daiichi Sankyo that general disclosures in patent applications are insufficient to support specific claims. The court invalidated Seagen's patent for the ADC Enhertu®, stating it lacked adequate description of the GGFG linker. This decision emphasizes the need for detailed disclosures in chemical and life sciences patents to meet written description requirements.
Jan 16, 2026
Eurasian Region Patent Term Extensions: A Comprehensive Overview - Wolters Kluwer
Russia's patent system for pharmaceutical extensions (PTE) has evolved since its launch in 2003, now allowing up to five additional years for eligible drugs. As of 2025, 326 PTEs have been identified, primarily for medicaments. The system has faced challenges, including lengthy processing times and invalidations, but continues to adapt, reflecting a balance between patent holders and public interest.
Jan 16, 2026
Uncovering Celltrion Inc: Could This Pharmaceutical Giant Be the Next Major Investment Opportunity?
Celltrion Inc, a Korean biotech firm, is gaining attention for its focus on biosimilars and global expansion, positioning itself as a key player in the healthcare market. While not a mainstream name, its strategy to offer cost-effective alternatives to expensive biologics could appeal to long-term investors. The stock, trading under ISIN KR7068270008, is seen as a potential strategic buy amid increasing global healthcare cost pressures.
Jan 16, 2026
US Supreme Court to Review Patent Dispute Over 'Skinny Label' with Amarin
The U.S. Supreme Court will hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa, following Hikma's appeal against a ruling that allowed Amarin to sue for patent infringement. The case could impact generic drug makers and "skinny labels," which aim to promote competition. Amarin's Vascepa, approved for lowering cholesterol, generated $228.6 million in 2024.
Jan 16, 2026
Supreme Court to examine 'skinny labeling' and access to generic medications - STAT News
The Supreme Court will review the issue of skinny labels for generic medicines, a practice allowing companies to market drugs for specific uses while avoiding patent infringement lawsuits. This tactic, crucial since the Hatch-Waxman Act, aims to enhance competition and improve consumer access to affordable medications. The decision could significantly impact the availability of generics in the market.
Jan 16, 2026
Supreme Court to Examine Case Regarding Skinny Labeling in Generic Pharmaceuticals
The Supreme Court will review a case on "skinny labeling" practices in the generic drug market, which could affect access to affordable medications. The dispute involves Amarin Pharma and Hikma Pharmaceuticals, focusing on whether generic companies can market drugs with streamlined labels without infringing on patents. The outcome may significantly impact competition and medication costs.
Jan 16, 2026
UK health authority greenlights increased dosage of Novo's Wegovy for individuals with obesity | WKZO
Britain's health regulator has approved a maximum weekly dose of 7.2 mg of Novo Nordisk's weight-loss drug Wegovy, administered as three injections for obesity patients. This new dosage expands treatment options beyond the previous 2.4 mg limit. The approval is part of a broader trend in GLP-1 drug availability, with a pill version of Wegovy pending regulatory review.
Jan 16, 2026
Jim Cramer Reports Pfizer CEO Not Prepared to Confront RFK Jr.
Pfizer Inc. (NYSE:PFE) shares have declined 4.7% over the past year, with UBS setting a Neutral rating and a $25 price target due to upcoming patent expirations. BMO maintains an Outperform rating at $30, citing potential revenue drops from its coronavirus business. Jim Cramer highlighted concerns over Pfizer's vaccine business amid scrutiny from Health Secretary RFK Jr.
Jan 15, 2026
Extended Use of Anti-Obesity Drugs Essential to Avoid Weight Rebound
Recent research highlights that long-term use of anti-obesity medications is essential to prevent weight regain. Studies show that discontinuing these drugs leads to weight return, emphasizing their importance in sustained weight management. Despite patient reluctance for permanent use, findings indicate consistent outcomes across various anti-obesity drugs.
Jan 15, 2026
Efforts to make weight-loss medications more affordable are fueled by disparities in access to these treatments - AFR
Doctors in Australia are urging pharmaceutical companies to reduce prices for weight-loss drugs, which can reach up to $700 monthly. This call comes as the government considers expanding access to these medications beyond individuals with diabetes and heart disease. Over 400,000 Australians currently pay for these treatments, highlighting affordability concerns despite relatively low global prices.
Jan 15, 2026
Generic versions of Ozempic are set to dominate the market soon | The Independent
Affordable generics of Ozempic, a diabetes and weight-loss drug from Novo Nordisk, are set to enter markets as patents on semaglutide expire in Canada, India, China, and Brazil. This could lower prices and increase access, challenging Novo Nordisk's dominance in the GLP-1 category. Meanwhile, Amazon Pharmacy now offers Wegovy, Novo Nordisk's oral GLP-1 pill, with competitive pricing.
Jan 15, 2026
Hims & Hers Shares Under Investigation Due to Reliance on Compounded GLP-1 Products
Hims & Hers faces growing investor concerns due to legal uncertainties surrounding its reliance on compounded GLP-1 agonist drugs amid an antitrust lawsuit against Eli Lilly and Novo Nordisk. Analysts from Bank of America and Evercore ISI have issued cautious ratings, highlighting potential risks to profitability and revenue. The upcoming quarterly report in February is expected to clarify the company's strategy amidst these challenges.
Jan 15, 2026
2026: Key Pharmaceuticals to Monitor in the Coming Year - DCAT Value Chain Insights
In 2026, several bio/pharmaceuticals are poised for launch or approval, potentially becoming blockbusters, according to Matthew Arnold from Clarivate. The article highlights 11 drugs on Clarivate’s "Drugs to Watch" list, emphasizing key trends in product innovation and the companies involved. For more insights, listeners can tune into the Production to Prescription podcast.
Jan 15, 2026
Building on the success of our biosimilar products, we will begin the development of new medications.
At the JPMorgan Healthcare Conference, Kim Kyung-ah, CEO of Samsung Bioepis, announced plans to develop new drugs, aiming to establish a "Korean Big Pharma" model. The company will expand its biosimilar portfolio to 20 by 2030 and has initiated clinical trials for its new antibody drug conjugate, SBE303. Samsung Bioepis generated 2 trillion won in biosimilar sales last year.
Jan 15, 2026
Generic versions of Ozempic are set to enter the market in large numbers.
Affordable, regulated versions of Ozempic, containing semaglutide, are set to enter global markets as patents expire in Canada, India, China, and Brazil. This could challenge Novo Nordisk's dominance in the obesity drug market. The introduction of generics may lower prices and expand access, while raising public health considerations regarding drug pricing and coverage.
Jan 15, 2026
Revolutionary Pill for Weight Loss: Wegovy's Latest Development Eliminates Need for Injections - NCHStats
Novo Nordisk's Wegovy, a popular weight-loss drug, is now available in an oral pill form, approved by the FDA in December 2025. This new formulation of semaglutide offers similar effectiveness to the injectable version, with an average weight loss of 13.6%. The pill is priced lower and accessible through pharmacies and telehealth platforms, reshaping the weight-loss industry.
Jan 15, 2026
Significant Action Taken Against Counterfeit Medications in Haridwar: Pharmaceutical Production Facility ...
Authorities in Haridwar have sealed a pharmaceutical manufacturing unit for producing substandard and potentially fake medicines. This crackdown, which took place on January 13, 2025, highlights ongoing efforts to combat the distribution of counterfeit drugs in the region.
Jan 14, 2026
Medios AG: The Under-the-Radar Pharma Company Transforming the Specialty Drug Supply Chain
Medios AG is transforming Germany's specialty pharma market by creating a data-driven platform that integrates wholesale, compounding, and logistics. This infrastructure ensures timely delivery of high-value oncology and autoimmune therapies. By focusing on personalized medicine and efficient logistics, Medios AG aims to enhance care quality while managing costs, positioning itself as a key player in the evolving healthcare landscape.
Jan 14, 2026
AbbVie Partners with TrumpRx for Tariff Relief and Greater Pricing Flexibility
AbbVie has partnered with the Trump administration to join TrumpRx, a direct-to-patient platform aimed at reducing drug prices in the U.S. In exchange for tariff exemptions, AbbVie will offer lower prices for drugs like Humira and Synthroid, while committing $100 billion to U.S. R&D and manufacturing over the next decade.
Jan 14, 2026
JPM26: Tryngolza poised to be the first fully owned blockbuster from Ionis - Yahoo Finance
Ionis' Tryngolza (olezarsen) is projected to be the company's first blockbuster drug, with CEO Brett Monia announcing increased revenue forecasts following its New Drug Application for severe hypertriglyceridemia (sHTG). The drug, already approved for familial chylomicronemia syndrome, showed significant efficacy in trials. Ionis anticipates multiple drug launches by 2028, including bepirovirsen and zilganersen.
Jan 14, 2026
Incorporating Artificial Intelligence and Machine Learning into the Process of Drug Discovery and Development
Pharmaceutical companies are increasingly integrating AI and machine learning to enhance drug development, as highlighted in a Capgemini report. Notable collaborations include SOPHiA GENETICS with MD Anderson for precision oncology, and Iktos partnering with Servier to optimize small-molecule therapeutics. AI is expected to transform R&D, reduce costs, and improve clinical trial efficiency, addressing challenges like poor solubility in drug candidates.
Jan 14, 2026
JPM26: Tryngolza poised to be the first fully owned blockbuster from Ionis.
Ionis Pharmaceuticals has raised its peak sales estimate for Tryngolza (olezarsen) to $2 billion, anticipating approval for a new indication in severe hypertriglyceridemia (sHTG). The drug, already approved for familial chylomicronemia syndrome, demonstrated significant efficacy in trials. CEO Brett Monia also highlighted upcoming Phase III readouts and potential launches of other pipeline candidates by 2028.
Jan 14, 2026
JP Morgan Healthcare Conference Showcases Transition to Oral Obesity Medications and AI-Powered Research Innovations
The 44th JP Morgan Healthcare Conference in San Francisco highlights two key themes: the evolution of obesity treatments and the integration of artificial intelligence in drug development. Companies like Novo Nordisk and Eli Lilly are shifting towards oral obesity medications, with Eli Lilly's orforglipron expected to gain FDA approval by 2026. Additionally, a ₹8,350.00 crores partnership between Nvidia and Eli Lilly aims to enhance AI-driven drug discovery.
Jan 14, 2026
FDA states that commonly used weight-loss medications do not need suicide warnings - Business Standard
The FDA has instructed Novo Nordisk and Eli Lilly to remove suicidal thoughts warnings from their weight-loss drugs, including Wegovy, Saxenda, and Zepbound. A comprehensive review found no increased suicide risk among users of these GLP-1 medications, ensuring consistent labeling across all FDA-approved GLP-1 receptor agonists.
Jan 14, 2026
JPM26: Regeneron aims to avoid excessive spending in mergers and acquisitions due to upcoming patent expirations of key assets.
Regeneron is focusing on developing next-generation assets and expanding indications for its blockbuster drugs, Eylea and Dupixent, as they approach patent expiry. CEO Leonard Schleifer announced a $6bn R&D investment by 2026. Eylea HD is gaining traction despite FDA setbacks, while Dupixent, co-marketed with Sanofi, has surpassed $19bn in annual sales.
Jan 14, 2026
Should You Consider Selling Your Eli Lilly Stocks? - The Globe and Mail
Eli Lilly leads the GLP-1 drug market with its injectable products Mounjaro and Zepbound, which account for 54% of its revenue. However, Novo Nordisk has launched a pill version of its GLP-1 drug, posing a competitive threat. Eli Lilly's stock valuation appears high, raising concerns about future growth as patent protections expire. Investors are advised to consider exiting their positions.
Jan 14, 2026
Analysis of News: German pharmaceutical sector expands, yet concerns over patents and tariffs cast a shadow on future prospects.
Germany's health and life sciences sector, led by companies like BioNTech and Bayer, continues to grow despite broader economic struggles. However, the industry faces challenges from patent expirations and increased U.S. tariffs, which threaten profitability. By 2030, drugs worth nearly $400 billion will lose patent protection, prompting companies to innovate and adapt to competition.
Jan 14, 2026
Should You Consider Selling Your Eli Lilly Stocks? - Yahoo Finance
Eli Lilly leads the GLP-1 drug market with its injectable products Mounjaro and Zepbound, which accounted for 54% of its revenue in 2025. However, concerns about future patent expirations and competition from Novo Nordisk's new pill version of its GLP-1 drug have investors cautious. To mitigate risks, Eli Lilly is expanding its pipeline through acquisitions like Adverum Biotechnologies and Ventyx Biosciences.
Jan 14, 2026
Should You Consider Selling Your Eli Lilly Stocks? - The Motley Fool
Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, have significantly boosted the company's revenue, accounting for 54% of it in 2025. However, competition is intensifying as Novo Nordisk introduces a GLP-1 pill, potentially impacting Eli Lilly's market share. Investors are advised to consider the high valuation and future challenges as the company prepares for a patent cliff.
Jan 14, 2026
Government Evaluates GTE Exemption for 11 Specialized Medications, Local Pharmaceutical Companies Encouraged to Submit Concerns
The pharmaceutical department has issued a public notice seeking objections from local manufacturers regarding the inclusion of additional formulations in the Global Tender Enquiry exemption list. Notable drugs under consideration include Donanemab, Marstacimab, Elranatamab, Tildrakizumab, and various Insulin Lispro presentations. Objections must be submitted by January 19, 2026, to promote domestic manufacturing.
Jan 14, 2026
Carbery predicts ongoing influence of GLP-1 on the nutrition sector through medical appetite regulation.
The recent overhaul of US dietary guidelines has ignited a debate regarding the roles of saturated fat and protein in nutrition. Experts are divided on the implications of these changes, which could influence dietary recommendations and public health policies moving forward.
Jan 14, 2026
Eli Lilly's $1 Billion Partnership with NVIDIA AI Lab: Potential Impact on Growth, Profit Margins, and Product Development (LLY)
NVIDIA and Eli Lilly and Company have launched an AI co-innovation lab in South San Francisco, investing up to $1 billion over five years. This collaboration aims to enhance drug discovery using NVIDIA's BioNeMo platform. The initiative could significantly impact Lilly's growth strategy, particularly in its GLP-1 obesity and diabetes franchise, while addressing risks associated with product concentration.
Jan 14, 2026
FDA seeks to eliminate suicide warnings from drugs such as Zepbound and Wegovy - KRIS 6 News
The FDA has proposed removing suicide warnings from popular weight-loss medications, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy and Saxenda, after a safety review found no increased risk of suicidal thoughts or behavior. This decision marks a significant development for these GLP-1 drugs, which are increasingly prescribed for weight management.
Jan 14, 2026
FDA seeks to eliminate suicide warnings from weight-loss drugs such as Zepbound and Wegovy.
The FDA has proposed removing suicide warnings from popular weight-loss medications, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy and Saxenda, after a safety review found no increased risk of suicidal thoughts or behavior. This decision marks a significant development for these GLP-1 drugs, which are increasingly prescribed for weight management.
Jan 14, 2026
Could Favorable Results for Camzyos Enhance BMY's Heart Health Offerings? - TradingView
Bristol Myers Squibb (BMY) reported positive results from the SCOUT-HCM trial for Camzyos, showing its effectiveness in treating adolescents with obstructive hypertrophic cardiomyopathy (oHCM). The study met its primary endpoint, supporting potential approval for a broader patient population. Meanwhile, BMY discontinued the Librexia study for milvexian but continues with other trials. Eliquis remains a key product in BMY's cardiovascular portfolio.
Jan 13, 2026
Delhi High Court's Zydus Decision: Will It Improve Access to Affordable Cancer Medications Amid Patent Issues?
The Delhi High Court has allowed Zydus Lifesciences to launch a biosimilar of Nivolumab, a costly cancer drug, before the patent expires. This ruling could significantly reduce treatment costs by 30-40%, improving access for patients in India. The decision emphasizes public interest over strict patent enforcement, potentially reshaping cancer care and funding in the country.
Jan 13, 2026
Telangana DCA Discovers Counterfeit 'Levipil 500' Tablets, Reports DrugsControl Media Services
The Telangana Drugs Control Administration (DCA) has seized counterfeit 'Levipil 500' Tablets, an anti-epileptic medication containing Levetiracetam. The fake drugs were being falsely marketed, raising concerns over patient safety.
Jan 13, 2026
Zydus receives approval from India to market a cost-effective cancer medication amid a patent conflict with Squibb.
An Indian court has lifted an injunction against Zydus Lifesciences, allowing the company to sell its biosimilar of the cancer drug Nivolumab. The Delhi High Court's decision, based on public interest and insufficient patent claims, marks a significant victory for affordable healthcare in India.
Jan 13, 2026
FDA states that commonly used weight-loss medications do not need suicide warnings - ABC News
Federal regulators have instructed drugmakers Novo Nordisk and Eli Lilly to remove warnings about suicidal thoughts from their weight-loss drugs, including Wegovy, Saxenda, and Zepbound. The FDA's comprehensive review found no increased suicide risk among users of these GLP-1 medications, ensuring consistent labeling across all FDA-approved GLP-1 receptor agonists.
Jan 13, 2026
FDA states that commonly used weight-loss medications do not need suicide warnings - WFMJ.com
The FDA's January 2024 preliminary review found no connection between certain drugs and suicidal thoughts or actions, although a small risk could not be entirely dismissed. A subsequent analysis has now alleviated those concerns, confirming the safety of the drugs in question.
Jan 13, 2026
FDA states that commonly used weight-loss medications do not need suicide warnings - Las Vegas Sun
The FDA has instructed Novo Nordisk and Eli Lilly to remove warnings about suicidal thoughts from their weight-loss drugs, including Wegovy, Saxenda, and Zepbound. A comprehensive review found no increased suicide risk among users of these GLP-1 medications, ensuring consistent labeling across all FDA-approved GLP-1 receptor agonists.
Jan 13, 2026
JPM26: Sanofi showcases notable advancements in strategy with a range of innovative medications.
Sanofi reported an 8.7% sales growth, generating $4.55bn from 12 new medicines and vaccines in 2025, driven by its blockbuster drug Altuviiio for hemophilia A, which earned $975m. At the J.P. Morgan Healthcare Conference, Sanofi outlined a strategy for sustained growth, focusing on R&D and a robust pipeline, including drugs like amlitelimab and duvakitug, to offset future revenue losses.
Jan 13, 2026
Biogen Launches New Venture at JP Morgan 2026 | PharmExec
At the 44th Annual JP Morgan Healthcare Conference, Biogen's CEO Christopher Viehbacher emphasized the company's strategy to diversify its pipeline beyond multiple sclerosis, launching new therapies for Alzheimer's, postpartum depression, and ALS. Biogen also announced the European Commission's approval of a high-dose regimen of Spinraza for spinal muscular atrophy, enhancing treatment options for patients.
Jan 13, 2026
Recent clinical research highlights the role of botanicals in GLP-1 studies - AgFunderNews
Gateway Health Alliances (GHA) has released new clinical data indicating that botanical extracts Dyglomera and CQR-300 enhance GLP-1 activity, a hormone linked to satiety. The study showed these extracts inhibit DPP-4, improving appetite regulation and metabolic health. This research positions GHA's products as potential natural alternatives to GLP-1 drugs like semaglutide, addressing accessibility issues in weight management.
Jan 13, 2026
Delhi High Court Approves Sale of Nivolumab Biosimilar at 70% Lower Price, Offering Hope to Cancer Patients
The Delhi High Court has permitted Zydus Lifesciences to sell a biosimilar of Nivolumab, originally developed by Bristol Myers Squibb, at nearly 70% lower cost. This ruling aims to enhance access to cancer treatment, particularly in underserved areas, while balancing patent rights with public health needs. Nivolumab is used for lung, kidney, and melanoma cancers.
Jan 13, 2026
Delhi High Court permits Zydus to market a more affordable biosimilar of the cancer medication Nivolumab for the benefit of the public.
The Delhi High Court has authorized Zydus Lifesciences to manufacture and sell its biosimilar of Bristol Myers Squibb's cancer drug Nivolumab, priced 70% lower than the original. The ruling aims to enhance access to life-saving treatments while requiring Zydus to maintain sales records until the BMS patent expires in May 2026.
Jan 13, 2026
Pfizer's CEO anticipates a booming consumer market for obesity medications similar to the success of Viagra - ET Pharma
Pfizer CEO Albert Bourla announced the company's plans to enter the booming consumer market for obesity drugs, similar to the success of Viagra. Following its $10 billion acquisition of Metsera, Pfizer aims to launch 10 phase 3 studies for obesity treatments. Bourla emphasized the company's commitment to obesity solutions while navigating challenges from patent expirations and price cuts in the U.S.
Jan 13, 2026
Concerns Grow Over Numerous Confiscations of Cough Syrups, Injections, and Mind-Altering Medications
Law enforcement agencies in India have conducted multiple operations revealing illegal diversion of prescription medicines, including narcotic cough syrups and psychotropic drugs. The seizures, particularly of codeine-based cough syrups, have raised significant concerns about misuse and the need for stricter regulations in the pharmaceutical sector.
Jan 13, 2026
U.S. FDA awards Breakthrough Therapy Designation to Ipsen's IPN60340 (ICT01) for first-line treatment...
Ipsen has received Breakthrough Therapy Designation from the FDA for its investigational therapy IPN60340, in combination with venetoclax and azacitidine, for first-line treatment of unfit acute myeloid leukemia. The designation is based on promising results from the EVICTION trial, showing high response rates and good tolerability, highlighting IPN60340's potential as a novel immunotherapy for this aggressive cancer.
Jan 13, 2026
Lexaria Expands Its GLP-1 Initiatives Through DehydraTECH Developments, New Patents, and Additional Funding
Lexaria Bioscience (LEXX) has focused its efforts on applying its DehydraTECH oral drug-delivery technology to leading GLP-1 drugs—semaglutide, tirzepatide, and liraglutide. The company completed a Phase 1b study in Australia, expanded its patent portfolio, and raised $9.5 million to meet growing GLP-1 demand. Analysts rate LEXX stock as a Buy with a $1.50 price target.
Jan 13, 2026
Effectiveness comparison of oral Chinese patent medicines for chronic conditions | JPR
A recent network meta-analysis of 76 randomized controlled trials involving 8,431 participants found that Chinese patent medicines (CPMs) significantly improve symptoms of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) compared to standard therapy. Shuangshi Tonglin Capsules (SSTL) emerged as the most effective treatment, enhancing pain relief and quality of life. However, the evidence quality remains low to moderate, necessitating further research.
Jan 13, 2026
2025 Global Industry Analysis of Modafinil (CAS 68693-11-8) - GlobeNewswire
A new report on Modafinil, titled "Modafinil (CAS 68693-11-8) Industry Research 2025," has been released by ResearchAndMarkets.com. It offers insights into the Modafinil market, including trends, applications, manufacturing methods, and forecasts up to 2029. The report analyzes market drivers, challenges, and pricing across regions such as Europe, Asia, and North America.
Jan 13, 2026
2025 Global Industry Analysis of Olanzapine (CAS 132539-06-1) - GlobeNewswire
A new report titled "Olanzapine Industry Research 2025" has been released by ResearchAndMarkets.com, detailing the global and regional market trends for Olanzapine (CAS 132539-06-1) from 2019 to 2024, with forecasts extending to 2029. The report covers market drivers, challenges, applications, manufacturing methods, and pricing across various regions, providing valuable insights into the Olanzapine market landscape.
Jan 13, 2026
Global Research on Quetiapine (CAS 111974-69-7) Industry for 2025: GlobeNewswire
A new report on Quetiapine, titled "Quetiapine Industry Research 2025," has been released by ResearchAndMarkets.com. It offers insights into the global market trends, applications, manufacturing methods, and forecasts up to 2029. The report analyzes market drivers, challenges, pricing, and regional dynamics across Europe, Asia, and North America, serving as a vital resource for stakeholders in the Quetiapine market.
Jan 13, 2026
The Department of Pharmaceuticals might exclude an additional 11 medications from public procurement regulations.
The Department of Pharmaceuticals (DoP) plans to exempt 11 additional drugs, including insulin and monoclonal antibodies, from public procurement rules. This proposal expands on a previous list of 84 drug formulations announced in November 2025, aiming to streamline the procurement process under the Global Tender Enquiry (GTE).
Jan 13, 2026
FDA states that commonly used weight-loss medications do not need suicide warnings - The Week
The FDA has instructed Novo Nordisk and Eli Lilly to remove warnings about suicidal thoughts from their weight-loss drugs, including Wegovy, Saxenda, and Zepbound. A comprehensive review found no increased suicide risk among users of these GLP-1 medications, ensuring consistent labeling across all FDA-approved GLP-1 receptor agonists.
Jan 12, 2026
Pharmaceutical companies discovered marketing medications as 'nutraceuticals' to bypass regulations.
Telangana's Drugs Control Administration has identified nine pharmaceutical companies marketing drugs as 'nutraceuticals' to bypass regulations. This practice raises concerns about safety and compliance in the pharmaceutical industry.
Jan 12, 2026
Delhi High Court approves Zydus to market Nivolumab biosimilar for cancer treatment in India - Mint
The Delhi High Court has allowed Zydus Lifesciences to market its biosimilar of nivolumab, an anti-cancer drug sold as Opdivo by E.R. Squibb & Sons LLC, citing public interest. The court modified a previous injunction, noting the patent expires in May 2026, and directed Zydus to maintain audited sales records during this period.
Jan 12, 2026
Delhi High Court Permits Zydus Lifesciences to Market Nivolumab Biosimilar for Cancer Treatment in India
The Delhi High Court has ruled in favor of Zydus Lifesciences, allowing it to market its biosimilar of the anti-cancer drug nivolumab, known as ZRC-3276, in India. The court emphasized public interest and the impending patent expiry of E.R. Squibb & Sons LLC's original drug, Opdivo, set for May 2026. Safeguards for patent compensation were also established.
Jan 12, 2026
Vidac Pharma has been notified by the USPTO about the issuance of one of its key patents.
Vidac Pharma Holdings Plc has received a Notice of Issuance from the USPTO for a core patent protecting its molecules that modulate hexokinase 2 (HK2) interactions with mitochondria. This patent, effective for up to 20 years, strengthens Vidac's intellectual property in developing anti-cancer drugs, including VDA-1102, which shows promise against advanced actinic keratosis and cutaneous T-cell lymphoma.
Jan 12, 2026
Judicial authorities should take public welfare into account prior to issuing injunctions on essential medications.
The Delhi High Court emphasized the need for courts to weigh public interest when considering injunctions against life-saving drugs. The court stated that the existence of a life-saving drug does not automatically protect it from being injuncted, highlighting the importance of balancing legal rights and public health.
Jan 12, 2026
Two additional Russian pharmaceutical firms receive approval to utilize semaglutide patents.
The Russian government has authorized PSK Pharma and Promomed Rus to use patents for semaglutide, originally developed by Novo Nordisk, without consent. This decision, made under Directive No. 3931-r and Directive No. 3885-r, aims to ensure medication supply amid health concerns. Novo Nordisk's Ozempic, used for diabetes and weight loss, was previously the sole semaglutide drug in Russia.
Jan 12, 2026
Industry Report on Bupropion Hydrochloride (CAS 31677-93-7) - GlobeNewswire
A new report titled "Bupropion Hydrochloride Industry Research 2025" has been released by ResearchAndMarkets.com, detailing the global market trends, applications, and manufacturing methods for Bupropion hydrochloride. The report forecasts market dynamics and prices up to 2029, providing insights into drivers, challenges, and key players across regions including Europe, Asia, and North America.
Jan 12, 2026
Clozapine (CAS 5786-21-0) Market Analysis 2025: Worldwide Overview - GlobeNewswire
A new report titled "Clozapine (CAS 5786-21-0) Industry Research 2025" has been released by ResearchAndMarkets.com, detailing the global and regional market trends for Clozapine from 2019 to 2024, with forecasts extending to 2029. The report covers market drivers, challenges, applications, manufacturing methods, and pricing across various regions, providing essential insights into the Clozapine market landscape.
Jan 12, 2026
Global Industry Report on Topiramate (CAS 97240-79-4) for 2025 - GlobeNewswire
A new report titled "Topiramate Industry Research 2025" has been released by ResearchAndMarkets.com, detailing the global market trends, applications, and manufacturing methods for Topiramate (CAS 97240-79-4). The report forecasts market dynamics and pricing trends up to 2029, providing insights into supply-demand scenarios and key players across various regions including Europe, Asia, and North America.
Jan 12, 2026
Delhi High Court Approves Zydus' Cancer Treatment ZRC-3276 in Spite of BMS Patent Dispute
The Delhi High Court has permitted Zydus Lifesciences to manufacture and sell its cancer drug ZRC-3276, a biosimilar of Nivolumab, overturning a prior injunction. The court emphasized the need for product-to-claim mapping in patent cases and highlighted public interest, noting ZRC-3276 could provide a more affordable treatment option for cancer patients.
Jan 12, 2026
Anthony Albanese's administration is poised to reduce the price of a popular weight-loss medication.
The Australian government is set to subsidize Wegovy, a weight-loss drug similar to Ozempic, for adults with obesity and cardiovascular disease, following recommendations from the Pharmaceutical Benefits Advisory Committee. Health Minister Mark Butler will negotiate prices with manufacturer Novo Nordisk, aiming to reduce costs for over 400,000 Australians currently paying high private prices.
Jan 12, 2026
Delhi High Court approves Zydus to market biosimilar of BMS's cancer medication Nivolumab.
The Delhi High Court has authorized Zydus Lifesciences to produce and market its biosimilar cancer drug, ZRC-3276, as the patent for the original drug, Nivolumab, approaches expiration. The court emphasized the importance of patient access to affordable treatment in its decision.
Jan 12, 2026
Zydus Achieves Significant Victory: Delhi High Court Permits Sale of Cancer Drug Biosimilar | Whalesbook
The Delhi High Court has authorized Zydus Lifesciences to manufacture and sell its biosimilar of Bristol Myers Squibb's cancer drug, Nivolumab, overturning a previous injunction. This ruling supports affordable treatment access as BMS's patent expires on May 2. Zydus's product, ZRC-3276, complies with regulations and the court has mandated sales record-keeping until the patent lapses.
Jan 12, 2026
Semaglutide Patent Expiration: A ₹50,000 Crore Boon for Indian Pharmaceutical Industry - SNS Insider
The impending patent expiry of semaglutide, used in drugs like Ozempic and Wegovy, presents a significant opportunity for Indian pharmaceutical companies, potentially unlocking over Rs. 50,000 crores in revenue. As patents lapse starting in 2024, generics are expected to drive down prices by 30-50%, enhancing patient access to diabetes and weight management treatments.
Jan 12, 2026
Novo Nordisk's CEO highlights that there are 1.5 million users of compounded GLP-1 medications in the United States.
Novo Nordisk CEO Mike Doustdar revealed that up to 1.5 million U.S. patients may be using cheaper compounded versions of GLP-1 drugs, highlighting a shift in demand for obesity treatments. The company, known for its drug Wegovy, warns against the risks of these unapproved alternatives. Novo recently launched a daily oral version of Wegovy priced at $149 to attract price-sensitive consumers.
Jan 12, 2026
An error with GLP-1 could lead to weight gain occurring four times more quickly than if one were to cease dieting and exercising.
A new study published in the BMJ reveals that stopping GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) can lead to rapid weight regain, potentially four times faster than ceasing diet and exercise alone. Participants regained nearly 22 pounds within a year after discontinuation, highlighting the need for sustainable weight loss strategies beyond medication.
Jan 12, 2026
Novartis plans to pursue additional small-scale acquisitions, according to the CEO.
Novartis CEO Vasant Narasimhan announced the company's commitment to strategic bolt-on deals at the J.P. Morgan healthcare conference, focusing on oncology, immunology, neuroscience, and cardiovascular medicine. The firm aims to address the patent cliff for drugs like Entresto, Xolair, and Cosentyx. Recent acquisitions include Avidity Biosciences for $12 billion and Regulus Therapeutics for up to $1.7 billion.
Jan 12, 2026
The integration of BTK inhibitors with CAR T-cell therapy demonstrates promise in improving effectiveness.
Recent research indicates that combining Bruton’s tyrosine kinase (BTK) inhibitors with chimeric antigen receptor (CAR) T-cell therapy may enhance treatment efficacy and reduce toxicities in B-cell malignancies. This strategy aims to improve anti-cancer activity while addressing severe side effects associated with CAR T-cell therapy. Further studies are underway to assess the long-term safety and effectiveness of this combination.
Jan 11, 2026
From US Psychotropic Exports to a Significant Morphine Seizure in Assam, Reports DrugsControl Media Services
Indian law enforcement has launched a nationwide anti-narcotics drive, leading to significant arrests and seizures of banned substances, including Lobazam-10, Morphine, and Proxiohm-Spas tablets. The crackdown targets the illicit drug trade, with operations conducted across multiple states, highlighting the ongoing battle against drug trafficking in the country.
Jan 11, 2026
Interest in Korea's biotech IPO market is rekindled by interest rate reductions and the expiration of patents - CHOSUNBIZ
The pharmaceutical-bio IPO market is reviving as companies like Adel, NEXTGEN Bioscience Inc., Kanaph Therapeutics, and SK Plasma prepare for listings amid improving market conditions. Adel, known for its Alzheimer's treatment ADEL-Y01, aims for an IPO after a significant licensing deal with Sanofi. Analysts predict increased activity due to patent expirations in Big Pharma, potentially creating a $256 billion sales gap.
Jan 11, 2026
Editorial | An Easy Approach to Reduce Prescription Medication Costs in the United States – MIR
As US prescription drug prices soar, political leaders, including President Donald Trump, aim to negotiate with pharmaceutical companies. Patent thickets, exemplified by AbbVie's Humira, hinder biosimilar market entry, keeping prices high. The EU's stricter patent standards allow earlier biosimilar access, saving patients billions. Reforming the US patent system could enhance competition and reduce costs for Americans.
Jan 11, 2026
Research reveals the rapid weight regain following the cessation of weight-loss medications - Japan Today
A study reveals that users of GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, regain weight four times faster after stopping the drugs compared to traditional diet and exercise. Participants lost an average of 15 kg on these medications but regained 10 kg within a year. Experts stress that these drugs are effective but require long-term use for sustained weight management.
Jan 11, 2026
Mounjaro Outpaces Wegovy in Monthly Prescription Numbers in South Korea - DongA Science
Eli Lilly's Mounjaro has surpassed Novo Nordisk's Wegovy as the top obesity treatment in South Korea, with 97,344 prescriptions in November. The global market for GLP-1 obesity drugs is projected to exceed 100 trillion KRW by 2025. Meanwhile, an oral version of Wegovy has been launched in the U.S., and generic versions are anticipated post-2026 patent expiration.
